October Pharma results, Q1 2025
Net profit, assets, equity and cash flow for Q1 2025, against the same period a year earlier, from the published financial statements.
Net profit57.28 millionEGP · +14.3% vs the same period a year earlier
Total assets1.44 billionEGP · +17.1% vs the same period a year earlier
Shareholders' equity627 millionEGP · −2.0% vs the same period a year earlier
Operating cash flow90.51 millionEGP · +54.3% vs the same period a year earlier
In short
- October Pharma's net profit for Q1 2025 was about 57.28 million EGP, up +14.3% from 50.13 million EGP in Q1 2024.
- Total assets at the end of Q1 2025 were about 1.44 billion EGP, and shareholders' equity about 627 million EGP.
- Operating cash flow for Q1 2025 was positive at 90.51 million EGP.
Key lines against the same period a year earlier
This periodQ1 2024Change
Net profit57.28 million50.13 million+14.3%
Gross profit181 million137 million+32.0%
Total assets1.44 billion1.23 billion+17.1%
Total liabilities816 million603 million+35.3%
Shareholders' equity627 million640 million−2.0%
Total liabilities and equity1.44 billion1.24 billion+16.1%
Operating cash flow90.51 million58.66 million+54.3%
Investing cash flow-482 thousand-22.4 million+97.8%
Financing cash flow-58.6 million-2.99 million−1859.9%
Net change in cash31.42 million33.27 million−5.6%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
October Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy